TrialCancer science2026

IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer.

Morihito Okada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.